DMYD B Stock Overview
Develops precision medicine therapies for the treatment of autoimmune diabetes.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Diamyd Medical AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr14.10 |
52 Week High | kr20.00 |
52 Week Low | kr6.41 |
Beta | 2.08 |
1 Month Change | 17.30% |
3 Month Change | -0.28% |
1 Year Change | 75.59% |
3 Year Change | -53.16% |
5 Year Change | 91.06% |
Change since IPO | 214.73% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Diamyd Medical's (STO:DMYD B) Cash Burn Rate
Feb 02We Think Diamyd Medical (STO:DMYD B) Needs To Drive Business Growth Carefully
Sep 22What You Need To Know About Diamyd Medical AB (publ)'s (STO:DMYD B) Investor Composition
Jan 22Here's Why Diamyd Medical's (STO:DMYD B) Statutory Earnings Are Arguably Too Conservative
Nov 30Shareholder Returns
DMYD B | SE Biotechs | SE Market | |
---|---|---|---|
7D | 9.5% | -2.6% | -2.1% |
1Y | 75.6% | 3.0% | 11.2% |
Return vs Industry: DMYD B exceeded the Swedish Biotechs industry which returned 3% over the past year.
Return vs Market: DMYD B exceeded the Swedish Market which returned 11.2% over the past year.
Price Volatility
DMYD B volatility | |
---|---|
DMYD B Average Weekly Movement | 11.8% |
Biotechs Industry Average Movement | 8.8% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.7% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: DMYD B's share price has been volatile over the past 3 months.
Volatility Over Time: DMYD B's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1984 | 26 | Ulf Hannelius | www.diamyd.com |
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.
Diamyd Medical AB (publ) Fundamentals Summary
DMYD B fundamental statistics | |
---|---|
Market cap | kr1.41b |
Earnings (TTM) | -kr120.18m |
Revenue (TTM) | kr282.00k |
4,986x
P/S Ratio-11.7x
P/E RatioIs DMYD B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DMYD B income statement (TTM) | |
---|---|
Revenue | kr282.00k |
Cost of Revenue | kr3.76m |
Gross Profit | -kr3.48m |
Other Expenses | kr116.70m |
Earnings | -kr120.18m |
Last Reported Earnings
Feb 29, 2024
Next Earnings Date
Jun 26, 2024
Earnings per share (EPS) | -1.21 |
Gross Margin | -1,234.75% |
Net Profit Margin | -42,617.73% |
Debt/Equity Ratio | 0% |
How did DMYD B perform over the long term?
See historical performance and comparison